Computational identification of novel natural inhibitors of glucagon receptor for checking type II diabetes mellitus
暂无分享,去创建一个
Sukriti Goyal | Abhinav Grover | Sonam Grover | Jaspreet Kaur Dhanjal | Durai Sundar | J. Dhanjal | D. Sundar | A. Grover | S. Goyal | Sonam Grover
[1] V. Ding,et al. Design and synthesis of conformationally constrained tri-substituted ureas as potent antagonists of the human glucagon receptor. , 2007, Bioorganic & medicinal chemistry letters.
[2] T. Gardella,et al. Identification of a contact site for residue 19 of parathyroid hormone (PTH) and PTH-related protein analogs in transmembrane domain two of the type 1 PTH receptor. , 2003, Molecular endocrinology.
[3] V. Ding,et al. Discovery of potent, orally active benzimidazole glucagon receptor antagonists. , 2008, Bioorganic & medicinal chemistry letters.
[4] B. Wulff,et al. Three Distinct Epitopes on the Extracellular Face of the Glucagon Receptor Determine Specificity for the Glucagon Amino Terminus* , 2003, Journal of Biological Chemistry.
[5] John J Irwin,et al. Virtual screening against metalloenzymes for inhibitors and substrates. , 2005, Biochemistry.
[6] Harald Schwalbe,et al. The Human Cdc37·Hsp90 Complex Studied by Heteronuclear NMR Spectroscopy* , 2009, Journal of Biological Chemistry.
[7] Jian Ding,et al. α2,6-hyposialylation of c-Met abolishes cell motility of ST6Gal-I-knockdown HCT116 cells , 2009, Acta Pharmacologica Sinica.
[8] Ruben Abagyan,et al. Refinement of Glucagon-like Peptide 1 Docking to Its Intact Receptor Using Mid-region Photolabile Probes and Molecular Modeling* , 2011, The Journal of Biological Chemistry.
[9] Margaret S. Wu,et al. Anti-Diabetic Efficacy and Impact on Amino Acid Metabolism of GRA1, a Novel Small-Molecule Glucagon Receptor Antagonist , 2012, PloS one.
[10] D. Moller,et al. A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects. , 2004, Diabetes.
[11] Bei B. Zhang,et al. Glucagon and regulation of glucose metabolism. , 2003, American journal of physiology. Endocrinology and metabolism.
[12] M. J. Charron,et al. Glucagon Receptor Knockout Prevents Insulin-Deficient Type 1 Diabetes in Mice , 2011, Diabetes.
[13] D. Drucker,et al. Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes. , 2009, American journal of physiology. Endocrinology and metabolism.
[14] C. Behrens,et al. Human glucagon receptor antagonists with thiazole cores. A novel series with superior pharmacokinetic properties. , 2009, Journal of medicinal chemistry.
[15] S. Qureshi,et al. Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the treatment of type II diabetes. , 2012, Journal of medicinal chemistry.
[16] M. Ezzati,et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants , 2011, The Lancet.
[17] Ruben Abagyan,et al. Mapping spatial approximations between the amino terminus of secretin and each of the extracellular loops of its receptor using cysteine trapping , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[18] T. Yaqub,et al. Identification of Determinants of Glucose-Dependent Insulinotropic Polypeptide Receptor That Interact with N-Terminal Biologically Active Region of the Natural Ligand , 2010, Molecular Pharmacology.
[19] Hege S. Beard,et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.
[20] Chris de Graaf,et al. Structure of the human glucagon class B G-protein-coupled receptor , 2013, Nature.
[21] Kuntal Pal,et al. Structure and mechanism for recognition of peptide hormones by Class B G-protein-coupled receptors , 2012, Acta Pharmacologica Sinica.
[22] C. Behrens,et al. New β-Alanine Derivatives Are Orally Available Glucagon Receptor Antagonists , 2007 .
[23] C. Behrens,et al. New beta-alanine derivatives are orally available glucagon receptor antagonists. , 2007, Journal of medicinal chemistry.
[24] Robert Kiss,et al. Virtual Fragment Docking by Glide: a Validation Study on 190 Protein-Fragment Complexes , 2010, J. Chem. Inf. Model..
[25] J M Thornton,et al. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. , 1995, Protein engineering.
[26] S. Hoare,et al. Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors. , 2005, Drug discovery today.
[27] V. Marks,et al. Effect of glucagon antibodies on plasma glucose, insulin and somatostatin in the fasting and fed rat , 1985, Diabetologia.
[28] Didier Rognan,et al. Structure‐Based Discovery of Allosteric Modulators of Two Related Class B G‐Protein‐Coupled Receptors , 2011, ChemMedChem.
[29] A. Engel,et al. PloS One 2012 , 2015 .
[30] W. Sherman,et al. Probing the α‐Helical Structural Stability of Stapled p53 Peptides: Molecular Dynamics Simulations and Analysis , 2010, Chemical biology & drug design.
[31] BMC Bioinformatics , 2005 .
[32] Matthew P. Repasky,et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.
[33] W. L. Jorgensen,et al. Comparison of simple potential functions for simulating liquid water , 1983 .
[34] D. Drucker,et al. Glucagon and glucagon-like peptide receptors as drug targets. , 2006, Current pharmaceutical design.
[35] L. Miller,et al. Structural basis of natural ligand binding and activation of the Class II G-protein-coupled secretin receptor. , 2007, Biochemical Society transactions.
[36] Ruben Abagyan,et al. Molecular Basis of Secretin Docking to Its Intact Receptor Using Multiple Photolabile Probes Distributed throughout the Pharmacophore* , 2011, The Journal of Biological Chemistry.
[37] M. Michael,et al. Glucagon as a target for the treatment of Type 2 diabetes , 2005, Expert opinion on therapeutic targets.